Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC

Clin Lung Cancer. 2020 Nov;21(6):562-567. doi: 10.1016/j.cllc.2020.05.009. Epub 2020 May 16.

¹ Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China; Division of Hematology/Oncology Department of Internal Medicine, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA.
² Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
³ Division of Hematology/Oncology Department of Internal Medicine, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA.
⁴ Division of Hematology/Oncology Department of Internal Medicine, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA. Electronic address: [email protected].
⁵ Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Electronic address: [email protected].

No abstract available

Keywords: Acquired resistance; EGFR mutation; EML4-ALK Variant 5; Histologic transformation; Metastatic NSCLC.

Publication types